Retatrutide Sourcing & Quality: The Enforcement Record

Read This First

This page is not built on clinical evidence. There are no trials of gray-market retatrutide, because there is no standardized product to trial. What exists instead is an enforcement record: FDA statements and warning letters, an import alert, a manufacturer's litigation, and one government health alert describing liver injury.

Retatrutide is not approved for human use anywhere in the world. Its manufacturer states this plainly: no medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world, and it cannot be sold to consumers.2

That places this compound in a different position from most of the library. It is not an obscure research chemical that regulators have not got round to. It is a Phase 3 asset whose published Phase 2 trial reported mean weight reduction of 24.2 percent at 48 weeks on the highest dose,8 one lawful route of access that is not a purchase, and an active enforcement campaign running against the people selling it. Lilly's own formulation is that retatrutide is an investigational molecule legally available only to participants in its clinical trials.10

Legal Status

Where Does Retatrutide Stand?

Investigational everywhere. Approved nowhere.

The distinction that matters for sourcing is narrower than approval, and the FDA has stated it directly. Under a heading naming the compound, the agency writes that retatrutide and cagrilintide cannot be used in compounding under federal law, and adds that these are not components of FDA-approved drugs and have not been found safe and effective for any condition.1

Read that against the semaglutide situation and the difference becomes clear. Compounded semaglutide occupies a contested legal space, argued over shortage lists and salt forms. Retatrutide occupies no such space. There is no lawful compounding pathway to argue about, because the compound is not eligible for one.

Why Is There No Compounding Route?

Compounding a bulk substance requires the substance to qualify under one of a small number of routes: a component of an approved drug, an entry on the relevant bulks list, or a subject of a USP monograph. Retatrutide satisfies none of them, and the FDA says so.1

The shortage mechanism that briefly opened large-scale compounding of semaglutide and tirzepatide cannot apply either. A shortage is a shortage of an approved product. Retatrutide has never been approved, so there is nothing for it to be in short supply of.

A clinic offering compounded retatrutide is not operating in a gray area of compounding law. It is operating outside it.

What Has the FDA Actually Done?

The agency lists three categories of recipient it has warned over this compound: telehealth companies marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers; active pharmaceutical ingredient distributors selling retatrutide and other GLP-1 drugs to compounders; and outsourcing facilities repackaging retatrutide.1

That is the whole supply chain, named at three levels: the people who sell it to consumers, the people who import the powder, and the facilities that put it into vials.

These are public documents. A seller's name appearing in that index is a matter of record rather than a matter of opinion, and the index is searchable.

What Is Happening at the Border?

The FDA operates a green list import alert, 66-80, covering GLP-1 active pharmaceutical ingredients with potential quality concerns. Shipments fall under Detention Without Physical Examination unless the manufacturer has been evaluated and listed as compliant.1

Retatrutide is named in that alert. In the version published on 21 August 2026, retatrutide appears in the product-code entries attached to Chinese manufacturers, where the listing turns on whether the importer description contains the word.7

The detail worth extracting is what that implies about origin. The compound reaching the consumer market is being screened as imported bulk powder from overseas API manufacturers, and the vetting the green list performs is of the manufacturer, not of any particular shipment a buyer receives.

The Manufacturer's Position

What Has Lilly Said and Done?

On 12 August 2026 Eli Lilly filed six lawsuits against US entities selling black-market retatrutide, naming a California cosmetic centre chain and five Texas peptide sellers and pharmacies.2

The scale figures in that announcement are the useful part. Lilly stated it has reported more than 14,000 websites, advertisements, social media posts and product listings unlawfully marketing retatrutide across more than 100 countries, and referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement and licensing boards.2

Lilly's chief medical officer, David A. Hyman, is quoted in the release: what is being sold on the black market is not a medicine, and is entirely unverified, unapproved and not worth the risk.2

Lilly holds an obvious commercial interest in this position, and that belongs alongside the quote. It does not dispose of the underlying facts, which come from the regulator rather than the company.

"Research Use Only"

Does the Label Do What Sellers Think It Does?

No, and there is now a document that shows exactly how it fails.

In its March 2026 warning letter to Gram Peptides, the FDA wrote that despite statements on the product labeling marketing the products for research use only, and not intended for human consumption, medical use, or veterinary use, evidence obtained from the website established that the products were intended to be drugs for human use.4

The evidence the agency cited was the seller's own product copy: that the compound influences appetite suppression, insulin sensitivity, thermogenesis and fat-oxidation models, and that it demonstrated significant potential for reducing body weight, improving glucose handling and enhancing lipid metabolism.4

The disclaimer and the sales pitch sat on the same page, and the agency read the page as a whole. Intended use is established by the totality of the marketing, not by the sentence that contradicts it.

The FDA states elsewhere that products of this kind are of unknown quality and potentially harmful, and urges consumers not to purchase them.1

The label is a liability position taken by the seller. It is not a regulatory category, it has not protected sellers who were tested against it, and it says nothing whatever about what is in the vial.

Product Identity

What Is Being Sold Under This Name?

Unknown, in any individual case, and that is not a rhetorical answer.

Retatrutide is a single investigational molecule with one manufacturer, and that manufacturer does not sell it. Every vial on the consumer market therefore originates somewhere other than the only entity that has ever made a characterized version of the compound. There is no approved reference product against which a buyer can compare anything.

Watch the Naming

Sellers rename the compound, and the renaming is not always harmless. The Gram Peptides letter records retatrutide offered as "GLP-1-R peptide" and tirzepatide offered as "GLP-2 peptide."4

The second of those is pharmacologically wrong. GLP-2 is a distinct hormone with a distinct receptor, and tirzepatide is not an agonist of it. A seller using that label is either obscuring the product deliberately or does not understand what they are selling. Neither reading recommends them.

The Victorian health alert records the same pattern in the other direction, listing products sold as "Retatrutide," "Reta," "R-10" and "R-20."3 Abbreviations and code names travel faster than the compound name across platforms that moderate for it.

Purity Testing Versus Identity Testing

A sample can be highly pure and be the wrong molecule. The failure modes a purity figure cannot detect include a truncated or misassembled sequence, a missing or incorrect side-chain modification, and a cheaper GLP-1 analog substituted outright — the last of which would still produce appetite suppression and weight loss, and so would not announce itself to the user.

A certificate reporting purity alone leaves all of that open.

Certificates of Analysis

What a Certificate Is

A document reporting laboratory results for a specific batch, typically identity and purity, sometimes more.

Read it for four things: which laboratory ran the analysis, the batch or lot number and whether it matches the vial in hand, the date, and which tests were performed as opposed to which the seller mentions in marketing.

What It Cannot Establish

It describes the batch that was tested, which may not be the vial received. Its value rests on a chain of custody between laboratory, seller and buyer that an end purchaser cannot independently verify.

A certificate is a PDF. Nothing about that format prevents reuse across batches or fabrication outright, and the FDA has documented fraudulent GLP-1 product labels naming compounding pharmacies that do not exist, and labels naming licensed pharmacies that did not make the product.1 Where labels have been fabricated, treating the accompanying document as self-verifying is not defensible.

The Liver Injury Signal

What Was Reported in Victoria?

This is the most specific documented harm attached to this compound's gray market, and it comes from a government health department rather than a forum.

On 19 June 2026 the Chief Health Officer of Victoria, Australia issued a health alert recording six cases of acute liver injury since January 2026 in people who had used an unapproved peptide product labelled as retatrutide. The products were bought online, through social media accounts and through friends.3

The reported presentation was tiredness or malaise, jaundice, abdominal pain, dark urine and abnormal bruising, with investigations showing transaminitis with possible raised bilirubin and coagulopathy.3

What the Alert Does and Does Not Say

This distinction is the whole value of the document, and it is routinely lost in secondary coverage.

The alert states that the toxic effects are possibly associated with a contaminant in the products, that the clinical presentation suggests additional contaminants may be contributing, and that further investigation of the contents of those products was underway.3

So: six confirmed liver injuries, a suspected contaminant, and no published analytical identification of what the contaminant was. Anyone citing this as proof that retatrutide damages the liver is overreading it. Anyone dismissing it because the contaminant was not identified is underreading it.

The department's own conclusion was categorical about scope rather than about mechanism: all products labelled as retatrutide are at risk, and people should not use any of them.3

That is what an unverified supply chain means in practice. The hazard was not attributable to the molecule on the label, which is precisely why it could not be anticipated by anyone reading the label.

What Is Not Known

Has Anyone Tested the Gray Market Systematically?

Not in any source ONPEPS can cite. We looked for peer-reviewed or laboratory-published analytical work on gray-market retatrutide, reporting purity, identity or contamination with a stated methodology and sample count. We did not find it.

That absence is worth stating explicitly, because the vacuum has been filled with numbers. Figures circulate describing what proportion of black-market retatrutide vials match their label. Where such a figure is quoted without a named laboratory, a sample count and a methodology, it cannot be traced to a primary source, and it should be treated as unverified however often it is repeated and whichever direction it points.

The honest position is that nobody has published a denominator. Neither the reassuring version nor the alarming version of that statistic is a measurement.

What About the Self-Reported Data?

One study has examined what people using unapproved retatrutide say happens to them. A 2026 preprint analyzed self-reported side effects among 13,589 Reddit users, classifying reports into standardized terms.9

Two caveats govern how far it can be taken. It is a preprint and has not been peer reviewed. And it measures what people write about symptoms, not what was in the product, which means it cannot separate the compound from the contaminants, the dose from the label, or a real effect from a reported one.

It is a description of a community's reports. It is not a safety dataset, and it is not chemistry.

Storage and Handling

What Is Known

For retatrutide specifically, no manufacturer-validated storage specification is publicly available, because no approved product exists. There is no published stability dataset for any preparation a consumer can buy.

What can be stated is general peptide chemistry and the regulator's guidance for this drug class. Lyophilized powder is more stable than peptide in solution. Heat accelerates degradation. Repeated freeze-thaw cycles stress peptides. Every specific duration circulating online for this compound is extrapolated from other molecules rather than measured on this one.

Cold Chain

Injectable GLP-1 drugs require refrigeration as stated in their package inserts. The FDA has received complaints that compounded GLP-1 drugs arrived warm or with inadequate ice packs, and recommends that patients not use any injectable GLP-1 drug that arrives warm or insufficiently refrigerated, because this can affect quality.1

A package arriving warm is one of the few quality failures a buyer can actually observe. It is worth acting on for that reason alone.

Multi-Dose Vials

Gray-market GLP-1 products are commonly supplied in vials holding several doses, and the FDA has addressed this directly. It recommends discarding a multi-dose sterile vial within 28 days of first use because of increased contamination risk after that point, even if medication remains, and even if the supplier's instructions say the vial may be used for longer. It also recommends a new sterile needle and syringe for every dose.1

The instruction to disregard a longer figure printed by the supplier is the agency's, not ours.

Signs to Stop Rather Than Proceed

• Incomplete dissolution, persistent cloudiness or visible particulate after gentle mixing

• Discoloration of powder or solution

• A package that arrives warm when cold-chain materials were promised

• Powder that is wet or clumped where a dry cake is expected

• A label, batch number or certificate that does not match what was ordered

None of these distinguishes between a different compound, degradation and contamination. What they share is that the material is not behaving as the label predicts. Appearance rules out some problems and confirms nothing, since a solution can be the wrong molecule entirely with no visible sign.

Community Language

Retatrutide

LY3437943. An investigational triple agonist at the GIP, GLP-1 and glucagon receptors, in Phase 3 trials and approved nowhere.

Reta, R-10, R-20

Names recorded by the Victorian Department of Health on products linked to acute liver injury.3

Research use only

A seller's liability position, not a regulatory category permitting human use. The FDA has held that the label does not survive marketing copy that establishes human therapeutic intent.4

Green list

The exemption schedule inside an import alert. Being on it means a manufacturer has been evaluated, not that a given shipment has been tested.

Certificate of analysis

A laboratory report on one batch. It describes the batch tested, not necessarily the vial received.

Triple agonist

Activity at three receptors rather than one or two. It describes a mechanism, not a verified product.

Related ONPEPS Coverage

• Retatrutide library entry: evidence, mechanism and regulatory status

• Retatrutide cost and access: why there is no price, and no legal route

• Compounded, gray market and counterfeit semaglutide: what the regulators have documented

• Tirzepatide library entry: the approved dual agonist

Sources

1. US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Drug Alerts and Statements. Content current as of 1 September 2026. fda.gov

2. Eli Lilly and Company. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. 12 August 2026. investor.lilly.com

3. Department of Health, Victoria, Australia. Toxicity linked to unapproved peptide product labelled Retatrutide. Health alert issued by Dr Caroline McElnay, Chief Health Officer, 19 June 2026. health.vic.gov.au

4. US Food and Drug Administration. Warning Letter: Gram Peptides. MARCS-CMS 721806, 31 March 2026. fda.gov

5. US Food and Drug Administration. Warning Letter: GLP-1 Solution. MARCS-CMS 715883, 9 September 2025. fda.gov

6. US Food and Drug Administration. Warning Letter: ASN-LABS. MARCS-CMS 716459, 9 September 2025. fda.gov

7. US Food and Drug Administration. Import Alert 66-80: Detention Without Physical Examination of Glucagon-Like Peptide-1 Receptor Agonist Active Pharmaceutical Ingredients. Published 21 August 2026. accessdata.fda.gov

8. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. Paywalled. pubmed.ncbi.nlm.nih.gov/37366315

9. Sehgal NKR, Tronieri JS, Rader B, Ungar L, Guntuku SC. Self-Reported Side Effects Among Reddit Users Taking Unapproved Retatrutide. medRxiv preprint, posted 3 June 2026. Preprint, not peer reviewed. doi.org/10.64898/2026.05.28.26352819

10. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, 21 May 2026. Company topline announcement, not peer reviewed. biospace.com

Not Medical Advice

Retatrutide holds no marketing authorization for human use in any jurisdiction, and its manufacturer states it cannot be sold to consumers.2 If you are already using a product obtained outside a pharmacy, the route back to oversight is a clinician who knows what you have taken. Given the Victorian liver injury cases, liver function testing is a reasonable thing to raise with them.3

Regulatory sources verified 5 September 2026. Enforcement activity against this compound is ongoing and the record changes frequently. Re-verify before relying on any statement here.